Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Vor Biopharma
Biotech
Vor Bio's dual stem cell, ADC shows consistent engraftment
Vor Bio plans to accelerate enrollment of a phase 1/2 trial of its dual stem cell-ADC cancer therapy to get a fuller picture of post-relapse response.
Max Bayer
Nov 9, 2023 4:10pm
Vor's cancer cell therapy gets on FDA's fast track
Sep 10, 2021 6:07am
J&J, Vor ally to assess bispecific and stem cell therapy in AML
Jul 9, 2021 7:50am
Vor Biopharma hits Wall Street with $177M IPO
Feb 5, 2021 3:25pm
Mukherjee debuts 2nd cell therapy biotech
Jan 6, 2021 9:58am
Vertex taps Atkinson to head manufacturing— Chutes & Ladders
Jul 17, 2020 9:30am
